Phase i trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma

Loren Michel, Jessica Ley, Tanya M. Wildes, András Schaffer, Anthony Robinson, Se Eun Chun, Wooin Lee, James Lewis, Kathryn Trinkaus, Douglas Adkins

Research output: Contribution to journalArticlepeer-review

55 Scopus citations

Abstract

Objectives To test the safety of the CDK4/6 inhibitor palbociclib with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Materials and Methods A phase I trial using 3+3 design was performed to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of palbociclib with standard dose weekly cetuximab. Palbociclib was administered orally days 1-21 every 28 days: dose level 1 (100 mg/d) and 2 (125 mg/d; approved monotherapy dose). Pharmacokinetic assessments were performed on cycle 2, day 15. Cyclin D1, p16INK4a, and Rb protein expression were measured on pre-treatment tumor. Tumor response was assessed using RECIST1.1. Results Nine patients (five p16INK4a negative; four positive) were enrolled across dose levels 1 (n = 3) and 2 (n = 6) and none experienced a DLT. A MTD of palbociclib was not reached. Myelosuppression was the most common adverse event. Six of nine patients had cetuximab-resistant and 4/9 had platin-resistant disease. Disease control (DC) occurred in 89%, including partial response (PR) in two (22%) and stable disease in six (67%) patients. PRs occurred in p16INK4a negative HNSCC. Five patients (56%) had measurable decreases in tumor target lesions. In cetuximab-resistant HNSCC, best tumor response was PR in 1 and DC in 5 and median TTP was 112 days (range: 28-168). In platin-resistant HNSCC, best tumor response: PR in 1, DC in 3 and median TTP was 112 days (range: 28-112). The Cmax and AUC0-24h appeared comparable in patients receiving 125 vs 100 mg dose of palbociclib. Conclusion This trial, the first to evaluate a CDK4/6 inhibitor in HNSCC, determined that palbociclib 125 mg/day on days 1-21 every 28 days with cetuximab was safe. Tumor responses were observed, even in cetuximab- or platin-resistant disease.

Original languageEnglish
Pages (from-to)41-48
Number of pages8
JournalOral Oncology
Volume58
DOIs
StatePublished - Jul 1 2016

Keywords

  • Cetuximab
  • Head and neck cancer
  • Palbociclib
  • Phase I
  • Squamous cell carcinoma

Fingerprint

Dive into the research topics of 'Phase i trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this